Drug Trial Radar · NCT07391605
Descartes-08 in Autoantibody Myositis
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Apr 28, 2026
Primary completion
Nov 2027
Study completion May 2028
Sponsor
- Lead sponsor
- Cartesian TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety and tolerability of an autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with autoantibody-mediated myositis, including antisynthetase syndrome (ASyS) and dermatomyositis (DM).
Conditions
- Antisynthetase Syndrome
Interventions
Descartes-08Drug
Autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA)
PlaceboOther
Plasma-Lyte
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major improvement of 2016 ACR/EULAR Total Improvement scoreTime frame: 24 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of California, Irvine
Orange, California · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
University of North Carolina
Chapel Hill, North Carolina · Recruiting
National Neuromuscular Research Institute
Austin, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.